205 related articles for article (PubMed ID: 23909468)
1. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia.
Maung SW; Leahy M; O'Leary HM; Khan I; Cahill MR; Gilligan O; Murphy P; McPherson S; Jackson F; Ryan M; Hennessy B; McHugh J; Goodyer M; Bacon L; O'Gorman P; Nee A; O'Dwyer M; Enright H; Saunders J; O'Keeffe D
Br J Haematol; 2013 Oct; 163(1):118-22. PubMed ID: 23909468
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases.
Bussone G; Ribeiro E; Dechartres A; Viallard JF; Bonnotte B; Fain O; Godeau B; Michel M
Am J Hematol; 2009 Mar; 84(3):153-7. PubMed ID: 19123460
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
[TBL] [Abstract][Full Text] [Related]
4. A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia.
Birgens H; Frederiksen H; Hasselbalch HC; Rasmussen IH; Nielsen OJ; Kjeldsen L; Larsen H; Mourits-Andersen T; Plesner T; Rønnov-Jessen D; Vestergaard H; Klausen TW; Schöllkopf C
Br J Haematol; 2013 Nov; 163(3):393-9. PubMed ID: 23981017
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
6. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia.
Barcellini W; Zaja F; Zaninoni A; Imperiali FG; Di Bona E; Fattizzo B; Consonni D; Cortelezzi A; Zanella A
Eur J Haematol; 2013 Dec; 91(6):546-51. PubMed ID: 24033754
[TBL] [Abstract][Full Text] [Related]
7. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
Peñalver FJ; Alvarez-Larrán A; Díez-Martin JL; Gallur L; Jarque I; Caballero D; Díaz-Mediavilla J; Bustelos R; Fernández-Aceñero MJ; Cabrera JR;
Ann Hematol; 2010 Nov; 89(11):1073-80. PubMed ID: 20526716
[TBL] [Abstract][Full Text] [Related]
8. A case of autoimmune haemolytic anaemia achieving complete response with rituximab.
Dev M; Mushtaq N; Faisal A
J Pak Med Assoc; 2014 Jun; 64(6):700-2. PubMed ID: 25252495
[TBL] [Abstract][Full Text] [Related]
9. [The long-term efficacy and safety of rituximab combined with cyclophosphamide in treatment of seven patients with refractory and recurrent autoimmune hemolytic anemia].
Liu H; Xing LM; Wang HQ; Wu YH; Qu W; Liang Y; Wang GJ; Song J; Wang XM; Guan J; Li LJ; Fu R; Shao ZH
Zhonghua Nei Ke Za Zhi; 2012 Jun; 51(6):456-9. PubMed ID: 22943757
[TBL] [Abstract][Full Text] [Related]
10. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
Heidel F; Lipka DB; von Auer C; Huber C; Scharrer I; Hess G
Thromb Haemost; 2007 Feb; 97(2):228-33. PubMed ID: 17264951
[TBL] [Abstract][Full Text] [Related]
11. Rituximab is an effective and safe treatment of relapse in elderly patients with resistant warm AIHA.
Laribi K; Bolle D; Ghnaya H; Sandu A; Besançon A; Denizon N; Truong C; Pineau-Vincent F; de Materre AB
Ann Hematol; 2016 Apr; 95(5):765-9. PubMed ID: 26858026
[TBL] [Abstract][Full Text] [Related]
12. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome.
Kemper MJ; Gellermann J; Habbig S; Krmar RT; Dittrich K; Jungraithmayr T; Pape L; Patzer L; Billing H; Weber L; Pohl M; Rosenthal K; Rosahl A; Mueller-Wiefel DE; Dötsch J
Nephrol Dial Transplant; 2012 May; 27(5):1910-5. PubMed ID: 22076431
[TBL] [Abstract][Full Text] [Related]
14. [Role of rituximab in the management of refractory autoimmune cytopenia].
Losa Frías V; García Sánchez AM; Ortiz Valentín I; González Vicent M; Velasco Arribas MR; Madero López L; Sevilla Navarro J
An Pediatr (Barc); 2013 Jun; 78(6):398-404. PubMed ID: 23266244
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients.
Roumier M; Loustau V; Guillaud C; Languille L; Mahevas M; Khellaf M; Limal N; Noizat-Pirenne F; Godeau B; Michel M
Am J Hematol; 2014 Sep; 89(9):E150-5. PubMed ID: 24847759
[TBL] [Abstract][Full Text] [Related]
16. A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-ITP1000 study).
Tran H; Brighton T; Grigg A; McRae S; Dixon J; Thurley D; Gandhi MK; Truman M; Marlton P; Catalano J
Br J Haematol; 2014 Oct; 167(2):243-51. PubMed ID: 25041261
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus is effective for primary refractory/relapsed warm autoimmune haemolytic anaemia/Evans syndrome: a retrospective single-center study.
Zhang Z; Hu Q; Yang C; Chen M; Han B
Ann Med; 2023; 55(2):2282180. PubMed ID: 37967535
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia.
Piatek CI; Bocian H; Algaze S; Weitz IC; O'Connell C; Liebman HA
Acta Haematol; 2020; 143(3):244-249. PubMed ID: 31665725
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.
Brah S; Chiche L; Fanciullino R; Bornet C; Mancini J; Schleinitz N; Jean R; Kaplanski G; Harlé JR; Durand JM
Ann Hematol; 2012 Feb; 91(2):279-85. PubMed ID: 21710166
[TBL] [Abstract][Full Text] [Related]
20. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial.
Ghanima W; Khelif A; Waage A; Michel M; Tjønnfjord GE; Romdhan NB; Kahrs J; Darne B; Holme PA;
Lancet; 2015 Apr; 385(9978):1653-61. PubMed ID: 25662413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
